ArticlePharmacoEconomics2026
A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.
Aidan J McGovern et al.PubMed ↗Publisher ↗
No numbers read from the abstract.